181586-07-2

Ono 3403 is a synthetic serine protease inhibitor hat inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock. Oral administration of the potent serine protease inhibitor ONO-3403 has an antitumor effect on malignant tumors suggested by the growth inhibition of mouse skin tumors in research.

ONO-3403 is an orally active serine protease inhibitor. ONO-3403 inhibits the production of TNF-α and nitric oxide induced by LPS. ONO-3403 inhibits the cell growth and induces the apoptosis, and has an antitumor effect on malignant tumors[1][2][3][4].

[1] Tumurkhuu G, et al. ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock. Innate Immun. 2011;17(1):97-105. DOI:10.1177/1753425909353641
[2] Hiwasa T, et al. Potent growth-suppressive activity of a serine protease inhibitor, ONO-3403, toward malignant human neuroblastoma cell lines. Cancer Lett. 1998;126(2):221-225. DOI:10.1016/s0304-3835(98)00015-9
[3] Ohkoshi M, et al. Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403. Anticancer Res. 2002;22(2A):821-823. PMID:12014657